hypertensive disorders in pregnancy ppt-2 [read … disorders in pregnancy by ... due to congestion...
TRANSCRIPT
02/02/2017
1
Hypertensive Disorders in
Pregnancy
By
Mr Yasir M Shaukat
ED SpR
Classification
1. PRE-EXISTING (CHRONIC) HYPERTENSION
1. PRE-ECLAMPSIA
3. ECLAMPSIA
02/02/2017
2
Pre-existing (chronic) hypertension:
–Hypertension is present before
pregnancy, detected in early pregnancy
and postpartum.
PRE-EXISTING (CHRONIC)
HYPERTENSION
Causes
• Essential hypertension: of unknown aetiology.
• Secondary to chronic renal disorder: e.g. – Glomerulonephritis.
– Hydronephrosis.
– Pyelonephritis.
– Renal artery stenosis.
• Secondary to cardiovascular disease: e.g. – Coarctation of the aorta.
– Polyartheritis nodosa.
– Systemic lupus erythematosus.
02/02/2017
3
PRE-EXISTING (CHRONIC)
HYPERTENSION
• Secondary to endocrine disorders: e.g.
– Primary aldosteronism.
– Phaeochromocytoma.
– Adrenocortical tumours.
– Diabetes mellitus.
Effect of Pregnancy on Chronic
Hypertension
• Blood pressure falls by the second trimester in
most of cases, but rises during the third
trimester to a level some what above that in
early pregnancy.
• Deterioration of the underlying disease.
02/02/2017
4
Effect of Chronic Hypertension on
Pregnancy
Maternal:
• superimposed pre-
eclampsia/ eclampsia in 15-
20% of cases
Foetal:
– Intra-uterine growth
retardation.
– Intra-uterine foetal death.
Treatment
• Rest
• Antihypertensives
• Observation
02/02/2017
5
Pregnancy-induced hypertension
(PIH):
– Transient hypertension:
• Late onset hypertension, without proteinuria or
pathologic oedema
– Pre-eclampsia:
• Hypertension with proteinuria and / or oedema after 20
weeks of pregnancy, but may be earlier
– Eclampsia:
• Pre-eclampsia + convulsions.
PRE-ECLAMPSIA
• Incidence: 5-10%.
• Multisystem disorder
• Develops after 20 weeks gestation
• Aetiology unknown
02/02/2017
6
Predisposing factors
• Primigravidae more than multigravidae.
• Pre-existing hypertension.
• Previous pre-eclampsia.
• Family history of pre-eclampsia.
• Obesity.
Signs
• Hypertension
• Proteinuria (albuminuria)
• Oedema
02/02/2017
7
Hypertension
• Blood pressure of 140/90 mmHg or more or an
increase of 30 mmHg in systolic and/or 15
mmHg in diastolic blood pressure over the pre-
or early pregnancy level.
Proteinuria (albuminuria)
• Urinary protein greater than 0.3gm/L in 24 hours collection or greater than 1gm/L in two random samples obtained at least 6 hours apart.
• Indicates glomerular damage and occurs after hypertension
• Proteinuria usually in range of 1-3 gm daily ,50-60% is albumin, in severe cases may exceed 15gm.
02/02/2017
8
Oedema
• Weight gain > 1 kg in any one week or 2.25 kg
in any one month.
• Clinical oedema in about two-thirds of patients
with PIH. However, two-thirds of pregnant
women with clinical oedema do not develop
hypertension.
Symptoms pre-eclampsia
• Headache: usually frontal, may be occipital. Due to cerebral oedema and hypertension.
• Visual disturbances: blurring of vision, flashes of light or blindness.
• Epigastric or right upper quadrant pain: due to enlargement or subcapsular haemorrhage of the liver.
• Nausea and vomiting: due to congestion of gastric mucosa and/ or cerebral oedema.
• Oliguria or anuria: due to kidney pathology.
02/02/2017
9
Investigations
• Complete urine examination: for proteinuria, pus cells, RBCs, casts, specific gravity, culture and sensitivity.
• Renal function tests: serum uric acid > 6 mg % is abnormal during pregnancy. It is more specific for pre-eclampsia than creatinine.
• FBC and Coagulation screen: Platelet count, fibrinogen and FDP as DIC may develop.
• Fundoscopy.
• Foetal well being: – ultrasound,
– daily foetal movement count,
– non-stress test,
– oxytocin challenge test (if needed).
• Imminent eclampsia: It is a state in which the patient is about to develop eclampsia. Usually there are:
– blood pressure much higher than 160 /110 mmHg,
– heavy proteinuria (+++or ++++),
– hyperreflexia,
– severe continuous headache,
– blurring of vision,
– epigastric pain.
02/02/2017
10
Why is Pre-eclampsia important?
• Foetal complications:– Prematurity
– IUGR
– IUD
– Acute foetal distress
• Maternal complications:– HTN
– Risk CVA
– Pulmonary oedema
– Renal failure
– Liver failure
– DIC
– Placenta abruptio
– Eclampsia
Management severe pre-eclampsia
• Treatment:– Control BP (anti-hypertensives)
– Prevent seizures (MgSO4)
– Fluid management
– Decide on mode and timing of delivery
• Observations:– Maternal
• Symptoms
• BP + HR
• Reflexes +/- clonus
• Urine protein
• Urine output
– Fetal• CTG
• USS or Doppler if indicated
• One-to-one midwife care
• Transfer to Labour ward when stable
02/02/2017
11
Anti-hypertensives
• Acute hypertensive crisis– Systolic BP >180
– Diastolic BP >110
– Mean arterial pressure >125
• Persistent hypertension– BP > 160/100
• Treatment– Acute: IV Labetalol/Hydralazine/GTN
– Persistent: Labetalol/Methyldopa/Nifedipine
Acute hypertensive crisis
• Aim BP 130-140/90-100
• Avoid too rapid fall in BP
• Continuous FHR monitoring
02/02/2017
12
Definition - Eclampsia
• Seizures in women with PIH/PE not due to
other causes
• Any seizure in pregnancy is usually treated as
eclampsia until proven otherwise
• Antenatally 38%, Intrapartum 18%,
Postpartum 44% (especially 1st 24h)
Management of seizure
• Seizures are usually self-limiting
• MgSO4 is anticonvulsant of choice– Both in controlling as well as preventing
– IV Diazepam is NOT the drug of choice, unless MgSO4 not available
• Avoid polypharmacy to treat seizures -> increase risk of respiratory arrest
• Protocol– Loading dose MgSO4 (4g over 10mins)
– Maintainance dose 1g/hr
– Usually continued for 24h after delivery or after the last convulsion
• Important: rapid injection of MgSO4 can cause cardiorespiratory arrest!
02/02/2017
13
Monitoring on MgSO4
• Hourly monitoring
• Patellar reflexes should be present• Absence earliest sign of toxicity
• RR: 12-16
• UOP: >30mL/hr
• O2 Sats
Management of MgSO4 toxicity
• UOP <100mL/4h:– Fluid challenge
– If no clinical signs toxicity � reduce rate to 0.5g/hr
• Absent patellar reflexes:– Stop MgSO4 infusion
– May resume if reflexes return
• Respiratory depression:– Stop infusion
– O2 and monitor closely
– HDU/ITU
• Respiratory/Cardiac arrest– Resuscitate
– Stop infusion
– IV Calcium Gluconate 10% 10mL IV over 3-5 mins
02/02/2017
14
Management of recurrent seizures
• 2nd bolus of MgSO4
• 2g if <70kg and 4g if >70kg
• Check deep tendon reflexes and RR before repeating dose
• If further seizures:– Diazepam
– Thiopentone
– Intubation
– Intermittent positive pressure ventilation and muscle relaxation
– CT Head to rule out bleed
Delivery
• In severe pre-eclampsia/eclampsia definitive Tx is delivery
• Delivery decision based on– Patient’s condition (Clinical/Biochemical)
– Gestational Age
• If delivery to be delayed and gestation less than 34 weeks– IM Dexamthasone 6mg BD for 48hours
– Close monitoring
02/02/2017
15
Post delivery care
• HDU Care for first 24-48h post delivery
• Fluid balance chart
• CAUTION - Majority eclamptic seizures occur AFTER delivery
• Reduce anti-hypertensives as indicated
• Repeat Investigations (FBC, Clotting, LFTs, U&E’s)
HELLP syndrome
• HELLP, a syndrome characterized by
Haemolysis, elevated liver enzyme levels
and a low platelet count, is an obstetric
complication that is frequently misdiagnosed
at initial presentation.
• Many investigators consider the syndrome to
be a variant of preeclampsia,
02/02/2017
16
HELLP syndrome
• In some cases , HELLP symptoms are the
first warning of pre-eclampsia
• Misdiagnosed as hepatitis, idiopathic
thrombocytopenic purpura, gallbladder
disease, or thrombotic thrombocytopenic
purpura
Epidemiology and Risk Factors
• HELLP syndrome 0.2 to 0.6 % of all pregnancies.
• Superimposed HELLP syndrome develops in 4 to 12 percent
of women with preeclampsia or eclampsia.
• Maternal mortality has been estimated to be as high as 2-24%
• Perinatal mortality is equally high, ranging from 9 –39 %.
02/02/2017
17
Clinical Presentation
• 90% of patients present with general malaise
• 65 % with epigastric pain
• 30 % with nausea and vomiting
• 31 percent with headache
• All are nonspecific symptoms
Clinical Presentation
• Early diagnosis of this syndrome is critical
• Any pregnant woman who presents with
malaise or a viral-type illness in the third
trimester should be evaluated with a complete
blood cell count and liver function tests
02/02/2017
18
Clinical Presentation
• The physical examination may be normal in patients with HELLP syndrome
• Right upper quadrant tenderness 90 %
• Oedema is not a useful marker
• Hypertension and proteinuria may be absent or mild.
Diagnosis
• Concurrence of hemolysis, elevated liver
enzymes, and low platelet count.
• However, there is obviously still a lack of
consensus on the laboratory parameters
and their cutoff values used to diagnose
02/02/2017
19
Laboratory Diagnostic Criteria for
HELLP syndrome
• Haemolysis Abnormal peripheral smear : spherocytes, schistocytes, triangular
cells and burr cellsTotal Bilirubin level > 1.2 mg/dLLactate dehydrogenase level > 600U/L
• Elevated liver function test resultSerum aspartate amino transferase level > 70U/L Lactate dehydrogenase level >600 U/L
• Low platelet countPlatelet count < 150 000/mm3
Platelet countappears to be the
most reliable
indicator of the
presence of HELLP
syndrome
02/02/2017
20
Management
• Delivery
• Corticosteroids
• Magnesium sulphate
• Antihypertensives
• Blood products
• Hypertension is controlled at less than 160/110
mm hg,
• Oliguria responds to fluid management .
• Elevated liver function values are not
associated with right upper quadrant or
epigastric pain.
• Class II –III .(platelet count).>50000
Eligibility to conservative
management
02/02/2017
21
Management
• Patients with HELLP syndrome should be treated prophylacticallywith magnesium sulfate to prevent seizures, whether hypertension is present or not.
• Antihypertensive therapy should be initiated if blood pressure is consistently greater than 160/110 mm hg despite the use of magnesium sulfate. The goal is to maintain diastolic blood pressure between 90 and 100 mm hg.
The most commonly used antihypertensive agent has been
� hydralazine
� Labetolol
� Nifedipine
Management
• Corticosteroid therapy should be instituted in
patients with HELLP syndrome who have a
platelet count of less than 100,000 per mm3
• Should be continued until liver function
abnormalities are resolving and the platelet
count is greater than 100,000 per mm3
02/02/2017
22
Management
• Between 38 -93 % of patients with
HELLP syndrome receive some form of
blood product.
• Patients with a platelet count greater than
40,000 per mm3 are unlikely to bleed.
• The mortality rate for women with HELLP syndrome is approximately 1.1 %
• From 1 to 25 % of affected women develop serious complications such as DIC, placental abruption, adult respiratory distress syndrome, hepatorenal failure, pulmonary edema, subcapsular hematoma and hepatic rupture.
• A significant percentage of patients receive blood products.
02/02/2017
23
• Infant morbidity and mortality rates range from 10 to 60 %, depending on the severity of maternal disease.
• Infants affected by HELLP syndrome are more likely to experience intrauterine growth retardation and respiratory distress syndrome.
• Patients with HELLP syndrome who complain of
severe right upper quadrant pain, neck pain or
shoulder pain should be considered for hepatic
imaging regardless of the severity of the
laboratory abnormalities, to assess for subcapsular
haematoma or rupture.
• by three to four days postpartum The laboratory
abnormalities in HELLP syndrome typically
worsen after delivery and then begin to resolve.